Related Experiment Video

Updated: Aug 9, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 16, 2013

Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1

David M Lonard1, Sophia Y Tsai, Bert W O'Malley

  • 1Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA.

Molecular and Cellular Biology
|December 16, 2003
PubMed

Insights

Selective estrogen receptor modulators (SERMs) like 4-hydroxytamoxifen and raloxifene increase coactivator protein levels. This unexpected finding suggests SERMs broadly stimulate nuclear receptor activity beyond estrogen receptor alpha.

Area of Science:

  • Molecular Biology
  • Endocrinology
  • Gene Regulation

Background:

  • Proteasome-mediated protein degradation is crucial for nuclear receptor-mediated gene expression.
  • Proteasome inhibition affects estrogen receptor alpha (ERalpha) activity and coactivator levels (SRC, CBP).
  • Selective estrogen receptor modulators (SERMs) are known to modulate ERalpha activity.

Purpose of the Study:

  • To investigate the impact of different ERalpha ligands, specifically SERMs, on coactivator protein levels.
  • To determine if SERM-induced changes in coactivators affect the transcriptional activity of other nuclear receptors.

Main Methods:

  • Treatment of HeLa cells with various ERalpha ligands, including 4-hydroxytamoxifen (4HT) and raloxifene.
  • Analysis of steady-state protein levels of SRC-1 and SRC-3 coactivators.
  • Assessment of ERalpha dependency for observed effects.
  • Measurement of transcriptional activity of other nuclear receptors following SERM treatment.

Main Results:

  • SERMs 4HT and raloxifene significantly elevate SRC-1 and SRC-3 protein levels in an ERalpha-dependent manner.
  • Increased coactivator protein levels correlate with enhanced transcriptional activity of other nuclear receptors.
  • SERM treatment leads to an unexpected broad stimulation of nuclear receptor transcriptional activity.

Conclusions:

  • SERMs exert effects beyond ERalpha modulation by increasing coactivator levels.
  • This mechanism contributes to a broader biological action of SERMs, stimulating multiple nuclear receptors.
  • Findings provide new insights into the complex tissue-specific responses to SERMs like 4HT and raloxifene.

More Related Videos

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay09:07

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay

Published on: December 19, 2018

An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects07:37

An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects

Published on: January 9, 2020

Related Concept Videos

Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...